Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer
byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m
Updated on: December 22,2023
10
Novel combination therapy has similar response rates to chemotherapy for high-risk luminal B breast cancer
byAmerican Association for Cancer ResearchNeoadjuvant treatment with the CDK4/6 inhibitor ribociclib (Kisqali) and the aromatase inhibitor letrozole (Femara) produced response rates similar to m
Updated on:December 22,2023
10
